What is Intelligent Bio Solutions Inc. (INBS) stock price today?

Intelligent Bio Solutions Inc. (INBS) currently trades at $4.11 per share. The stock has a market capitalization of $6.77M and a P/E ratio of —x.

Is INBS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Intelligent Bio Solutions Inc. has a Smart Value Score of 38/100 (Grade D), resulting in a "Sell" rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -14.28.

What is the INBS stock price target?

WallStSmart's 12-month consensus price target for Intelligent Bio Solutions Inc. is $12.00 (+192.0% versus the current $4.11). Our DCF model estimates intrinsic value at $4.26.

What is Intelligent Bio Solutions Inc.'s revenue and earnings?

Intelligent Bio Solutions Inc. has trailing twelve-month (TTM) revenue of $3.91M with profit margins of -296.80%. Earnings per share (EPS) is $-11.62.

Is Intelligent Bio Solutions Inc. financially healthy?

Intelligent Bio Solutions Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -14.28 places it in the distress.

Is INBS stock overvalued or undervalued?

Based on our DCF model, Intelligent Bio Solutions Inc.'s intrinsic value is $4.26, representing a margin of safety of -23.2% versus the current price of $4.11. The stock trades at a P/E of —x.

INBS

Intelligent Bio Solutions Inc.

NASDAQ: INBS · HEALTHCARE · MEDICAL DEVICES

$4.11

-3.94% today

Updated 2026-06-03

Market cap

$6.77M

P/E ratio

—

P/S ratio

1.73x

EPS (TTM)

$-11.62

Dividend yield

—

52W range

$2 – $25

Volume

0.1M

Market cap

$6.77M

P/E ratio

—

P/S ratio

1.73x

EPS (TTM)

$-11.62

Dividend yield

—

52W range

$2 – $25

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

6.3

Growth

6.0

Quality

2.0

Profitability

4.0

Valuation

2/9

Piotroski F-Score

Weak

-14.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →210 stocks currently score above 75

Price targets

Analyst target

$12.00

+191.97%

12-Month target

—

Intrinsic (DCF)

$4.26

Margin of safety

-23.24%

Price chart

Stock snapshot

Strengths

+ Revenue growth 45.50% QoQ

+ Debt/equity 0.21x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -14.28 — distress zone

- Thin margins at -296.80%

- Negative free cash flow $-4.49M

- 23.24% above intrinsic value

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$1.26M	$3.11M	$3.05M	$3.91M
Net income	$-8.31M	$-10.63M	$-10.16M	$-10.57M	$-2.86M
EPS	—	—	—	—	$-11.62
Free cash flow	$-3.74M	$-7.88M	$-9.79M	$-9.91M	$-4.49M
Profit margin	—	-845.89%	-326.40%	-346.23%	-296.80%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INBS	$6.77M	38	6.3	2.0	4.0	6.0	-23.24%	Hold
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-64.70%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-48.91%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-17.40%	Buy
AZN	$286.37B	64	6.0	8.5	6.0	5.0	+4.85%	Buy

Smart narrative

Intelligent Bio Solutions Inc. trades at $4.11. Our Smart Value Score of 38/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -14.28, it sits in the distress. TTM revenue stands at $3.91M. with profit margins at -296.80%. Our DCF model estimates intrinsic value at $4.26.

Frequently asked questions

What is Intelligent Bio Solutions Inc.'s stock price?

Intelligent Bio Solutions Inc. (INBS) trades at $4.11, on a P/S of 1.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Intelligent Bio Solutions Inc. overvalued?

Intelligent Bio Solutions Inc. carries a Smart Value Score of 38/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $4.26 against the $4.11 price, so on cash flow terms the market is paying a premium for Intelligent Bio Solutions Inc.'s growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.

What is the price target of Intelligent Bio Solutions Inc. (INBS)?

The 12-month analyst consensus target is $12.00, about 192.0% above the current $4.11. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

What is the intrinsic value of Intelligent Bio Solutions Inc. (INBS)?

Our DCF model estimates intrinsic value at $4.26, a -23.2% margin of safety versus today's $4.11. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.

What is Intelligent Bio Solutions Inc.'s revenue?

Intelligent Bio Solutions Inc.'s trailing twelve-month revenue is $3.91M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Altman Z-Score?

Intelligent Bio Solutions Inc.'s Altman Z-Score is -14.28, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.73x

ROE-170.20%

Beta4.24

50D MA$3.03

200D MA$8.19

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

INBS vs LLY →INBS vs JNJ →INBS vs ABBV →Stock screener →